4BIO Capital co-led the $18M seed round of Undecimal Bio, a company developing siRNA delivery beyond the liver using its DELiveri platform of novel conjugate molecules.
OCT 12, 2026
A Cambridge-based platform biotechnology company developing targeted delivery of siRNA therapeutics
A Cambridge-based platform biotechnology company developing targeted delivery of siRNA therapeutics. Its DELiveri platform uses AI to identify and optimize conjugates that direct RNA molecules to specific cells, addressing delivery challenges in RNA interference; the company is also advancing renovascular programs.